Feb 7 |
Curis Q4 2023 Earnings Preview
|
Feb 1 |
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
|
Dec 18 |
Curis, Inc. (NASDAQ:CRIS) Surges 54% Yet Its Low P/S Is No Reason For Excitement
|
Dec 12 |
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
|
Dec 11 |
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
|
Dec 6 |
Curis Announces Three Presentations at ASH
|
Dec 5 |
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
|
Nov 3 |
Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript
|
Nov 3 |
Curis Inc (CRIS) Reports Q3 2023 Financial Results: Net Loss Decreases Year-Over-Year
|
Nov 2 |
Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript
|